News & Updates

Show Multimedia Only

Optic neuropathy may induce vision loss in highly myopic eyes

11 Jan 2024

Optic neuropathy is the cause of vision impairment in 9.0 percent of eyes of highly myopic patients, according to a study. This rate is lower than the prevalence of myopic macular degeneration (MMD) as reason behind vision loss, which stands at 18.9 percent.

Optic neuropathy may induce vision loss in highly myopic eyes

11 Jan 2024

PDE5is do not induce ocular adverse events

10 Jan 2024

Use of phosphodiesterase 5 inhibitor (PDE5i) for erectile dysfunction (ED) or benign prostatic hyperplasia (BPD) does not seem to heighten the risk of ocular events in men, reveals a study.

PDE5is do not induce ocular adverse events

10 Jan 2024

Alzheimer's disease medications may protect against AMD

07 Jan 2024

Older adults with Alzheimer's disease who are receiving treatment with acetylcholinesterase inhibitors (AChEIs) appears to have a small reduction in the risk of age-related macular degeneration (AMD), as reported in a study.

Alzheimer's disease medications may protect against AMD

07 Jan 2024

Retinoblastoma treatment carries increased risk of neutropenia

30 Dec 2023

Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.

Retinoblastoma treatment carries increased risk of neutropenia

30 Dec 2023

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

Extended depth of focus soft contact lenses slows myopia progression in children

13 Dec 2023

Wearing soft contact lenses with extended depth of focus reduces axial elongation and, in turn, delays the progression of myopia in children when compared with using distance single-vision spectacles, as shown in a study.

Extended depth of focus soft contact lenses slows myopia progression in children

13 Dec 2023

Photoreceptor thinning linked to genetic AMD susceptibility in Asians

08 Dec 2023 by

Thinner photoreceptor layers in the central macula appear indicative of genetic predisposition to age-related macular degeneration (AMD) in healthy Asians, as shown in a study from Singapore.

Photoreceptor thinning linked to genetic AMD susceptibility in Asians

08 Dec 2023

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Use of immunosuppressants does not appear to increase the incidence of all-cause and cancer mortality in patients with noninfectious ocular inflammatory disease (OID) over a median follow-up of 10 years, a recent study has shown.

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Placebo effect delivers in open-angle glaucoma

07 Nov 2023

Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.

Placebo effect delivers in open-angle glaucoma

07 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Optic neuropathy may induce vision loss in highly myopic eyes

Optic neuropathy may induce vision loss in highly myopic eyes

PDE5is do not induce ocular adverse events

PDE5is do not induce ocular adverse events

Alzheimer's disease medications may protect against AMD

Alzheimer's disease medications may protect against AMD

Retinoblastoma treatment carries increased risk of neutropenia

Retinoblastoma treatment carries increased risk of neutropenia

Brolucizumab noninferior to aflibercept for diabetic macular edema

Brolucizumab noninferior to aflibercept for diabetic macular edema

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Extended depth of focus soft contact lenses slows myopia progression in children

Extended depth of focus soft contact lenses slows myopia progression in children

Photoreceptor thinning linked to genetic AMD susceptibility in Asians

Photoreceptor thinning linked to genetic AMD susceptibility in Asians

Immunosuppression does not raise risk of overall, cancer mortality

Immunosuppression does not raise risk of overall, cancer mortality

Placebo effect delivers in open-angle glaucoma

Placebo effect delivers in open-angle glaucoma